RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | 0.32 | -8.20 | -0.14 |
| FCF Yield | 1.01% | -6.33% | 5.61% | 1.06% |
| EV / EBITDA | 45.80 | -103.02 | 22.28 | 21.78 |
| Quality | ||||
| ROIC | -3.26% | -5.66% | 12.67% | 12.46% |
| Gross Margin | 79.86% | 87.11% | 92.06% | 88.45% |
| Cash Conversion Ratio | -0.37 | 2.22 | 1.74 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.12% | -11.86% | 38.13% | 17.69% |
| Free Cash Flow Growth | 108.95% | -164.96% | 455.69% | 158.49% |
| Safety | ||||
| Net Debt / EBITDA | 1.65 | 29.94 | -3.44 | -2.25 |
| Interest Coverage | -1.16 | -50.50 | 144.49 | 486.84 |
| Efficiency | ||||
| Inventory Turnover | 3.73 | 1.66 | 27.25 | 30.40 |
| Cash Conversion Cycle | 144.18 | 255.46 | -113.11 | 118.13 |